Evidence map›Paper›PMID 34951132›Full record

ArticleCancer medicine2022

Mouse characteristics that affect establishing xenografts from hepatocellular carcinoma patient biopsies in the United States.

Chenhui Zou, Imane El Dika, Koen O A Vercauteren, Marinela Capanu, Joanne Chou, Jinru Shia, Jill Pilet, Corrine Quirk, Gadi Lalazar, Linda Andrus and 8 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.1field-weighted citation impact, top 51% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 6 institutions in 3 countries.

Chenhui ZouDivision of Gastroenterology and Hepatology, Weill Medical College at Cornell University, New York, New York, USA.
Imane El DikaDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Koen O A VercauterenLaboratory of Virology and Infectious Disease, The Rockefeller University, New York, New York, USA.
Marinela CapanuDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Joanne ChouDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Jinru ShiaDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Jill PiletLaboratory of Virology and Infectious Disease, The Rockefeller University, New York, New York, USA.
Corrine QuirkLaboratory of Virology and Infectious Disease, The Rockefeller University, New York, New York, USA.
Gadi LalazarDivision of Gastroenterology and Hepatology, Weill Medical College at Cornell University, New York, New York, USA.
Linda AndrusLaboratory of Virology and Infectious Disease, The Rockefeller University, New York, New York, USA.
Mohammad KabbaniLaboratory of Virology and Infectious Disease, The Rockefeller University, New York, New York, USA.
Amin YaqubieDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Danny KhalilDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Taha MergoubMemorial Sloan Kettering Cancer Center, Sloan Kettering Institute, New York, New York, USA.
Luis ChiribogaDepartment of Pathology, Center for Biospecimen Research and Development, NYU Langone Health, New York, New York, USA.
Charles M RiceLaboratory of Virology and Infectious Disease, The Rockefeller University, New York, New York, USA.
Ghassan K Abou-AlfaDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.ORCID 0000-0002-1522-8054
Ype P de JongDivision of Gastroenterology and Hepatology, Weill Medical College at Cornell University, New York, New York, USA.
Memorial Sloan Kettering Cancer Center · USRockefeller University · USCornell University · USEuropean Organisation for Research and Treatment of Cancer · NLMedizinische Hochschule Hannover · DENYU Langone Health · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
Toward Safer Gene Therapy for Hemophilia AP01HL160472 · NHLBI · INDIANA UNIVERSITY INDIANAPOLIS · PI Roland W. Herzog · 2022 to 2026
$15.1M
Modeling human hepatotropic infections in complex tissue organoidsR01DK085713 · NIDDK · ROCKEFELLER UNIVERSITY · PI BHATIA, SANGEETA N., RICE, CHARLES M · 2009 to 2013
$5.6M
Modeling alcohol toxicity in human hepatocytesR01AA027327 · NIAAA · WEILL MEDICAL COLL OF CORNELL UNIV · PI DE JONG, YPE PETER · 2019 to 2023
$1.9M
The role of innate immune evasion in hepatitis C virus infectionK08DK090576 · NIDDK · WEILL MEDICAL COLL OF CORNELL UNIV · PI DE JONG, YPE PETER · 2011 to 2015
$760k
NCI NIH HHS P30 CA008748NHLBI NIH HHS P01 HL160472NIAAA NIH HHS R01 AA027327NIDDK NIH HHS K08 DK090576NIDDK NIH HHS R01 DK085713
6 · The paper itself

Abstract

backgroundHepatocellular carcinoma (HCC) patient-derived xenograft (PDX) models hold potential to advance knowledge in HCC biology to help improve systemic therapies. Beside hepatitis B virus-associated tumors, HCC is poorly established in PDX.

methodsPDX formation from fresh HCC biopsies were obtained and implanted intrahepatically or in subrenal capsule (SRC). Mouse liver injury was induced in immunodeficient Fah

resultsUsing rising hAAT as a marker for PDX formation, 20 PDX were established out of 45 HCC biopsy specimens (44%) reflecting the four major HCC etiologies most commonly identified at Memorial SloanKettering similar to many other institutions in the United States. PDX was established only in severely immunodeficient mice lacking lymphocytes and NK cells. Implantation under the renal capsule improved PDX formation two-fold compared to intrahepatic implantation. Two out of 18 biopsies required murine liver injury to establish PDX, one associated with hepatitis C virus and one with alcoholic liver disease. PDX tumors were histologically comparable to biopsy specimens and 75% of PDX lines could be passaged.

conclusionsUsing cycling off nitisinone-induced liver injury, HCC biopsies implanted under the renal capsule of severely immunodeficient mice formed PDX with 57% efficiency as determined by rising hAAT levels. These findings facilitate a more efficient make-up of PDX for research into subset-specific HCC.

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsAnimalsBiopsyDisease Models, AnimalHeterograftsHumansMiceUnited StatesXenograft Model Antitumor AssaysFah−/− micehuman alpha1-antitrypsinnitisinonePDX

Identifiers

PMID34951132
PMCPMC8817074
OpenAlexW4200180255

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.